

**EPHMRA**  
**ANATOMICAL CLASSIFICATION**  
**GUIDELINES 2019**

**Section A**

**Changed Classes/Guidelines: Changes Highlighted**

**Final Version**

**Date of issue: 24th December 2018**

<b>A3</b>	<b>FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS</b>	R2003
<b>A3A</b>	<b>PLAIN ANTISPASMODICS AND ANTICHOLINERGICS</b>	R1993
	Includes all plain synthetic and natural antispasmodics and anticholinergics.	
<b>A3B</b>	Out of use; can be reused.	
<b>A3C</b>	<b>ANTISPASMODIC/ATARACTIC COMBINATIONS</b>	
	This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4.	
<b>A3D</b>	<b>ANTISPASMODIC/ANALGESIC COMBINATIONS</b>	R1997
	This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1.	
<b>A3E</b>	<b>ANTISPASMODICS COMBINED WITH OTHER PRODUCTS</b>	r2011
	Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here.	
<b>A3F</b>	<b>GASTROPROKINETICS</b>	r2013
	This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9.	
	Combinations of gastroprokinetics with other substances are classified here if used for dyspepsia or gastro-oesophageal reflux.	
<b>A3G</b>	<b>GASTRO-INTESTINAL SENSORIMOTOR MODULATORS</b>	r201 <del>9</del> 4
	Products which are specifically developed to modulate the multiple symptoms of irritable bowel syndrome (IBS). Includes alosetron, tegaserod.	
	Linaclotide (290mcg) indicated for IBS-C (irritable bowel syndrome with constipation) is classified here; linaclotide (145mcg) indicated for chronic constipation is classified in A6A9. <u>Products containing linaclotide for both chronic constipation and for IBS-C are classified here when there is no distinction by strength.</u> Lubiprostone (8mcg) indicated for IBS-C is classified here; lubiprostone (24mcg) indicated for chronic constipation is classified in A6A9. <u>Products containing plecanatide indicated for chronic constipation and IBS-C are classified here.</u> Other drugs for constipation, including laxatives, are classified in A6A.	

<b>A6</b>	<b>DRUGS FOR CONSTIPATION AND BOWEL CLEANSERS</b>	r2014
	Includes laxatives and other products for constipation. Products that are both laxatives and bowel cleansers are classified in the appropriate laxative class. For the classification of products indicated for irritable bowel syndrome with constipation (IBS-C) see A3G.	
<b>A6A</b>	<b>DRUGS FOR CONSTIPATION</b>	r2014
<b>A6A1</b>	<b>Faecal softening laxatives</b>	r2015
	Includes products containing softening laxatives such as liquid paraffin or docusate sodium. Combinations of faecal softening laxatives with osmotic laxatives are classified here. Combinations with bulk-forming laxatives are classified in A6A3. Combinations with stimulant laxatives are classified in A6A2.	
	For castor oil products see A6A2. Glycerol suppositories are classified in A6A9.	
<b>A6A2</b>	<b>Stimulant laxatives</b>	r2013
	Includes products containing laxatives that have a stimulant effect on the intestinal membrane and peristalsis. Many of these are herbal, eg senna, or of herbal origin (anthraquinones, emodines, glycosides, etc). This group also includes phenolphthalein-derivatives, bisacodyl, and sodium picosulphate when used as a laxative. Products containing a stimulant laxative in combination with other laxative substances (except bulk-forming) are classified here.	
<b>A6A3</b>	<b>Bulk-forming laxatives</b>	r2013
	Includes products containing substances such as bran, ispaghula, methylcellulose, sterculia. Products containing a bulk-forming laxative in combination with other types of laxative are classified here.	
<b>A6A4</b>	<b>Enemas</b>	R2015
	Includes all products for constipation in enema form. Other rectal forms for constipation are classified as appropriate in the other constipation classes. Glycerol suppositories and effervescent suppositories are classified in A6A9.	
	Combination packs containing an enema and another form are classified according to the other form.	
<b>A6A5</b>	<b>Out of use</b>	D2013

A6A6	<p><b>Osmotic laxatives</b></p> <p>Includes products containing osmotic laxatives. Substances include lactitol, lactulose, macrogols, magnesium citrate, magnesium hydroxide, magnesium sulphate, mannitol, sorbitol, etc. Combinations with other laxative substances are classified in A6A1, A6A2 and A6A3. Combinations with electrolytes that are present to ensure a neutral impact on electrolyte levels are classified in A6A7.</p>	I2013
A6A7	<p><b>Osmotic laxatives with electrolytes</b></p> <p>Includes products containing osmotic laxatives in combination with electrolyte substances. These specific electrolytes are present to ensure a neutral impact on electrolyte levels.</p>	I2013
A6A9	<p><b>Other drugs for constipation</b></p> <p>Includes other drugs for constipation and combinations of laxatives not classified in A6A1-A6A7. Combinations of laxatives with centrally acting anti-obesity substances are classified in A8A.</p> <p>Glycerol suppositories and effervescent suppositories are classified here.</p> <p>Prucalopride for chronic constipation is classified here. Linaclotide (145mcg) indicated for chronic constipation is classified here; linaclotide (290mcg) indicated for IBS-C (irritable bowel syndrome with constipation) is classified in A3G. <u>Products containing linaclotide for both chronic constipation and for IBS-C are classified in A3G when there is no distinction by strength.</u> Lubiprostone (24mcg) indicated for chronic constipation is classified here; lubiprostone (8mcg) indicated for IBS-C is classified in A3G. <u>Products containing plecanatide and indicated for both chronic constipation and IBS-C are classified in A3G.</u></p>	r201 <del>95</del>

A7	<p><b><u>ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTI-INFLAMMATORIES</u></b>  <b><u>INTESTINAL DISORDER PRODUCTS</u></b></p> <p><u>Products for functional gastro-intestinal disorders are in A3 and products for constipation and bowel cleansing are in A6.</u></p>	R1993 r2019
A7A	<p><b>INTESTINAL ANTI-INFECTIVES</b> <del>ANTIDIARRHOEALS</del></p> <p>Includes all products containing one or more intestinal anti-infectives with or without other substances <u>that are used for diarrhoea and/or hepatic encephalopathy</u>. Sulphonamides and special antibacterials such as polymyxin, neomycin, vancomycin or colistin in oral form, when mainly indicated as antidiarrhoeals are included in this group. Combinations with motility inhibitors, intestinal adsorbants and micro-organisms are also included.</p> <p>Products containing rifaximin for either diarrhoea or hepatic encephalopathy are classified here. <u>Products containing fidaxomicin for <i>Clostridium difficile</i> intestinal infections are classified here.</u></p>	r2019 <del>8</del>
A7B	<p><b>INTESTINAL ADSORBENT ANTIDIARRHOEALS</b></p> <p>Includes products such as kaolin and pectin. Combinations with micro-organisms are also included.</p>	r2011
A7C	<p>Out of use; can be reused.</p>	
A7D	<p>Out of use; can be reused.</p>	
A7E	<p><b>INFLAMMATORY BOWEL DISORDER PRODUCTS</b></p> <p>Includes products for inflammatory bowel disorders. Immunosuppressant products used for inflammatory bowel disorders as well as other conditions are classified in L4, for example in L4B (anti-TNF products).</p>	R2017
A7E1	<p><b>Intestinal aminosalicylate products</b></p> <p>Includes products containing balsalazide, mesalazine, olsalazine, sulfasalazine and similar aminosalicylates for inflammatory bowel disorders. Products containing aminosalicylates and indicated for rheumatoid arthritis are classified in M1C.</p>	I2017
A7E2	<p><b>Intestinal corticosteroid products</b></p> <p>Includes products containing corticosteroids for inflammatory bowel disorders.</p>	I2017
A7E9	<p><b>Inflammatory bowel disorder products, other</b></p> <p>Includes other products for inflammatory bowel disorders. Products containing vedolizumab and indicated for inflammatory bowel disease only are classified here.</p>	<del>r2019</del> 7

Products containing disodium cromoglicate and indicated for food allergy are classified here.

[Darvadstrocel \(allogenic stem cells\) for perianal fistulae in Crohn's disease are classified here.](#)

<b>A7F</b>	<b>ANTIDIARRHOEAL MICRO-ORGANISMS</b>  Includes micro-organisms such as lactobacillus acidophilus which are indicated for the treatment of diarrhoeal disease. Excluded are combinations with other antidiarrhoeals such as anti-infectives, motility inhibitors and intestinal adsorbents.	I1993
<b>A7G</b>	<b>ORAL ELECTROLYTE REPLACERS</b>  Oral electrolyte replacers are included in this group where diarrhoeal disease has been indicated. Intravenous preparations are included in K.	I1993
<b>A7H</b>	<b>MOTILITY INHIBITORS</b>  Includes narcotic derivatives such as loperamide, diphenoxylate and paregoric. Combinations with intestinal adsorbents and micro-organisms are also included.	I1993
<b>A7X</b>	<del><b>ALL OTHER ANTIDIARRHOEALS</b></del> <b><u>INTESTINAL DISORDER PRODUCTS, OTHER</u></b>  Includes <del>all</del> <u>other products for intestinal disorders, including</u> antidiarrhoeal products.	<del>I1993</del> <u>2019</u>

<b>B</b>	<b>BLOOD AND BLOOD FORMING ORGANS</b>	
<b>B1</b>	<b>ANTITHROMBOTIC AGENTS</b>	R1994
<b>B1A</b>	<b>VITAMIN K ANTAGONISTS</b>  Includes coumarin and indanedione derivatives.	R2004
<b>B1B</b>	<b>HEPARINS</b>	R2004
B1B1	<b>Unfractionated heparins</b>  Includes injectable high molecular weight (unfractionated) heparin (pure and in combination with other substances) with an average molecular weight from 5000 up to 30000 Dalton. The molecules are unfractionated.	
B1B2	<b>Fractionated heparins</b>  Includes injectable low molecular weight (fractionated) heparin (pure and in combination with other substances) with an average molecular weight from 2000 up to 18000 Dalton. The molecules are fractionated (fragments). Included are, eg bemiparin, enoxaparin, tedelparin and tinzaparin.	R2003
B1B3	<b>Heparins for flushing</b>  Includes heparin products for use with catheters eg Hepflush, Heplock.	
B1B9	<b>Other heparins</b>	R2004
<b>B1C</b>	<b>PLATELET AGGREGATION INHIBITORS</b>  Includes all products claiming platelet aggregation inhibition as the main indication eg ticlopidine. Also included are those products which have specific packs or presentations which are mainly indicated for platelet aggregation inhibition. These products, such as sulphinpyrazone, ditazole, dipyridamole, aspirin and non-steroidal anti-inflammatories are also prescribed for other conditions.	r2017
B1C1	<b>Cyclo-oxygenase inhibitor platelet aggregation inhibitors</b>  Includes specific presentations of eg acetylsalicylic acid (aspirin), indobufen, picotamide, sulfinpyrazone, which are mainly indicated for platelet aggregation inhibition.  All oral solid low-dose aspirin products (162mg and below) are classified in B1C1 worldwide.	R2010

B1C2	<b>ADP (adenosine diphosphate) receptor antagonist platelet aggregation inhibitors</b>  Includes clopidogrel and ticlopidine.	I2000
B1C3	<b>GP IIb/IIIa (glycoprotein) antagonist platelet aggregation inhibitors</b>  Includes abciximab, eptifibatide and tirofiban.	I2000
B1C4	<b>Platelet cAMP enhancing platelet aggregation inhibitors</b>  Includes prostacyclin derivatives eg beraprost, iloprost, limaprost and also phosphodiesterase (PDE) inhibitors eg anagrelide, dipyridamole when mainly indicated for platelet aggregation inhibition. Products containing epoprostenol are classified in C6B3. Products containing prostacyclin derivatives and only indicated for PAH are classified in C6B3. Products containing prostacyclin derivatives and indicated for both PAH and other conditions are classified here.	R2017
B1C5	<b>Platelet aggregation inhibitors, combinations</b>  Includes combinations of two of more platelet aggregation inhibitors, eg a cyclo-oxygenase inhibitor with an ADP receptor antagonist, or a cyclo-oxygenase inhibitor with a PDE inhibitor.  Products containing a combination of a platelet aggregation inhibitor together with another substance and for use as antithrombotics are classified here.	R2004
B1C9	<b>Other platelet aggregation inhibitors</b>  Includes eicosapentanoic acid, nifedipine, ozagrel, vorapaxar.	r2015
<b>B1D</b>	<b>FIBRINOLYTICS</b>  Includes endogenous proteins (eg urokinase), exogenous proteins (eg streptokinase) as well as anisoylated plasminogen-streptokinase activator complex (APSAC) and pro-urokinase (a precursor form of urokinase).	R2004
<b>B1E</b>	<b>DIRECT THROMBIN INHIBITORS</b>  Includes argatroban, bivalirudin, desirudin, lepirudin, melagatran, ximelagatran.	I2004
<b>B1F</b>	<b>DIRECT FACTOR XA INHIBITORS</b>  Includes products containing direct factor Xa inhibitors, eg apixaban, <u>betrixaban</u> , edoxaban, rivaroxaban.	<del>r</del> 2019 3

<b>B2D</b>	<b>BLOOD COAGULATION</b>	
B2D1	<b>Factor VIII, <u>including substitutes</u></b>	<del>rR200</del> <u>52019</u>
	Includes antihaemophilic globulin A, <u>emcizumab, etc.</u> Products containing von Willebrand factor only are classified in B2D9.	
B2D2	<b>Factors II, VII, IX and X</b>	
	Includes antihaemophilic globulin B and prothrombin complex.	
B2D3	<b>Anti-inhibitor-coagulation complex</b>	R2003
	Includes aPCC (activated prothrombin complex concentrate), activated FVII (FVIIa), and eptacog alfa.	
B2D4	<b>Factor XIII</b>	
B2D5	<b>Fibrinogen</b>	
B2D6	<b>Fresh frozen plasma and antihaemophilic plasma</b>	
B2D7	<b>Cohn-Fraction I</b>	
B2D8	<b>Platelet concentrates</b>	
B2D9	<b>Other blood fractions</b>	R2005
	Includes products containing von Willebrand factor (single ingredient).	
<b>B2E</b>	<b>THROMBOPOIETIN AGONISTS</b>	I2012
	Includes products containing thrombopoietin agonists, such as eltrombopag and romiplostim.	
<b>B2F</b>	<b>TISSUE SEALING PREPARATIONS</b>	r2016
	Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.	
<b>B2G</b>	<b>SYSTEMIC HAEMOSTATICS</b>	<del>rR200</del> <u>62019</u>
	Tissue extracts with haemostatic activity, and including snake venoms causing blood clotting, and hormone products exclusively promoted as haemostatics. <u>Includes products containing parenteral conjugated oestrogens for control of uterine bleeding.</u>	



<p><b>D5</b></p>	<p><b>NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). <del>Combinations with corticosteroids, if not specifically indicated for psoriasis, are classified in D7B.</del> Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p>	<p>r201<del>90</del> 9</p>
<p><b>D5A</b></p>	<p><b>TOPICAL ANTIPSORIASIS PRODUCTS</b></p> <p>Includes products, containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, <u>salicylic acid</u> for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar <u>or salicylic acid</u> for psoriasis are classified here. <u>These products may also be for other inflammatory skin conditions.</u></p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p>	<p><del>r201</del> 095</p>
<p><b>D5B</b></p>	<p><b>SYSTEMIC ANTIPSORIASIS PRODUCTS</b></p> <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing secukinumab or ustekinumab and indicated for psoriasis and also other <u>non-skin</u> conditions, eg arthritis, are classified in L4C. <u>Psoriatic arthritis is defined as a skin condition. Apremilast is classified here if only for psoriatic skin conditions.</u></p>	<p>r201<del>98</del></p>
<p><b>D5X</b></p>	<p><b>OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8. Products containing topical fluorouracil for actinic keratosis are classified in L1B.</p> <p>Products containing dupilumab for atopic dermatitis <u>only</u> are classified here. <u>Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</u></p>	<p>r201<del>98</del></p>

<b>D7</b>	<b>TOPICAL CORTICOSTEROIDS</b>	
<b>D7A</b>	<b>PLAIN TOPICAL CORTICOSTEROIDS</b>	
	Includes all dermatological products containing one or more corticosteroids and no other active ingredient. Topical anabolic steroids are classified in D3A.	
<b>D7B</b>	<b>TOPICAL CORTICOSTEROID COMBINATIONS</b>	<u>r2019</u>
	Includes all dermatological products containing corticosteroids in combination with one or more active ingredients, except those classified in <u>D5A or D10A</u> . It should be noted that, in the classification, the term antibacterial includes antibiotics, sulphonamides and antiseptics.	
	Also the basic criterion which determines the classification for products of this nature is the type of anti-infective product (antibacterial, antifungal or combination of the two) which is in combination with the corticosteroid. If the product in combination with the corticosteroid is not an anti-infective the product should <del>automatically</del> be classified in D7B4.	
D7B1	<b>Combinations of corticosteroids with antibacterials</b>	<u>r2019</u> <u>R2002</u>
	If, in addition to corticosteroid and antibacterial or bacteriostatic (including antiseptic) agents (eg <del>salicylic acid</del> , hexachlorophene) the product also contains non-anti-infective ingredients such as an antihistamine, local anaesthetic, oestrogen, urea, etc then it should still be classified in D7B1.	
D7B2	<b>Combinations of corticosteroids with antifungals</b>	
	If, in addition to corticosteroids and antifungal agents, the product also contains non-anti-infective ingredients such as an antihistamine, local anaesthetic, urea, etc then it should still be classified in D7B2.	
D7B3	<b>Combinations of corticosteroids with antibacterials and antifungals</b>	
	It should be noted that if a product contains not only corticosteroid + antibacterial + antifungal but also additional ingredients such as urea, an antihistamine, etc it should still be classified in D7B3.	
D7B4	<b>Other corticosteroid combinations</b>	<u>rR200</u> <u>42019</u>
	<del>This would include</del> <u>Includes</u> combinations of corticosteroids with all other types of products including, for example, antihistamines, local anaesthetics, etc. Combinations of corticosteroids with coal tar <u>or salicylic acid</u> and <del>specifically</del> for psoriasis are classified in D5A; <u>these products may also be for other inflammatory skin conditions as well as psoriasis.-</u>	

<b>D11</b>	<b>OTHER DERMATOLOGICAL PREPARATIONS</b>	
<b>D11A</b>	<p data-bbox="316 241 1401 288"><b>OTHER DERMATOLOGICAL PREPARATIONS</b></p> <p data-bbox="316 324 1401 510">Includes medicated shampoos, medicated soaps, scalp lotions (other than in D5A, D1A3, D7B, D8A, D10A). Products for pigmentation disorders, systemic products for the treatment of dermatological conditions, anti-corn agents (plasters, tinctures, including products with salicylic acid especially formulated for warts, corns and calluses etc), and hair-restorers are classified in this group.</p> <p data-bbox="316 548 1401 622">Products containing finasteride 1mg and for alopecia are classified here. Products containing finasteride 5mg and for BPH are classified in G4C3.</p> <p data-bbox="316 660 1401 698">Products containing extracts of chamomile are classified in D3A.</p> <p data-bbox="316 736 1401 775">Psoralens, when used for inflammatory conditions, are classified in D5.</p> <p data-bbox="316 813 1401 851"><u>Products containing sirolimus gel for tuberous sclerosis are classified here.</u></p>	r201 <del>9</del> 8

<b>G2</b>	<b>OTHER GYNAECOLOGICALS</b>	
<b>G2A</b>	<b><u>LABOUR INDUCERS/UTEROTONIC PRODUCTS</u></b>	<u>r2019</u>
	<u>Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage.</u> Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	
<b>G2B</b>	<b>TOPICAL CONTRACEPTIVES</b>	
<b>G2C</b>	Out of use; can be reused from 2000.	D1997
<b>G2D</b>	<b>PROLACTIN INHIBITORS</b>	R1999
	This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc. Bromocriptine in lower doses (1 mg, 2.5 mg) for sexual disorders is classified here; higher doses for parkinsonism are in N4A. In Japan, bromocriptine is classified in N4A.	
<b>G2E</b>	<b>LABOUR INHIBITORS</b>	I1997
	This group includes products acting as labour inhibitors eg ritodrine.	
<b>G2F</b>	<b>TOPICAL SEX HORMONES</b>	<del>I1997</del> <u>2019</u>
	This group includes all topical hormones and/or steroids indicated for gynaecological conditions. <u>Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C.</u>	
<b>G2X</b>	<b>OTHER GYNAECOLOGICAL PRODUCTS</b>	I1997
<b>G2X1</b>	<b>Gynaecological antispasmodics</b>	I1997
	This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	
<b>G2X9</b>	<b>Other gynaecologicals</b>	r2016
	Specific products included in this class are non-hormonal anti-inflammatories (eg benzydamine) which are indicated specifically to treat gynaecological conditions. Includes lubricants for intimate vaginal use only. Includes products (lactogogues) for the promotion of milk production.	
	Products containing paroxetine (7.5mg daily) and indicated for menopausal vasomotor symptoms are classified here.	
	Products containing flibanserin and indicated for hypoactive sexual desire disorder (HSDD) in women are classified here.	



<p><b>G3C</b></p>	<p><b>OESTROGENS, EXCLUDING G3A, G3E, G3F</b></p> <p>Oestrogens in combination with non-hormonal substances are classified here.</p> <p>Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified here.</p> <p><u>Includes transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect.</u></p> <p><u>Products containing parenteral conjugated oestrogens for uterine bleeding are classified in B2G.</u></p>	<p>r201<del>9</del>5</p>
<p><b>G3D</b></p>	<p><b>PROGESTOGENS, EXCLUDING G3A, G3F</b></p>	<p>R1997</p>
<p><b>G3E</b></p>	<p><b>ANDROGEN WITH FEMALE HORMONE COMBINATIONS</b></p>	
<p><b>G3F</b></p>	<p><b>OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A</b></p>	
<p><b>G3G</b></p>	<p><b>GONADOTROPHINS, INCLUDING OTHER OVULATION STIMULANTS</b></p>	
<p><b>G3H</b></p>	<p>Out of use; can be reused from 2009.</p>	<p>D2006</p>
<p><b>G3J</b></p>	<p><b>SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS)</b></p> <p>Included in this class are products that contain selective oestrogen receptor modulators, eg lasofoxifene, raloxifene. When primarily indicated for cancer, SERMs are classified in L2.</p> <p>Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified in G3C.</p>	<p>r2015</p>
<p><b>G3X</b></p>	<p><b>OTHER SEX HORMONES AND SIMILAR PRODUCTS</b></p> <p>Includes mammary extracts and other hormonal preparations for sexual disorders eg placenta extracts. Cyproterone acetate (tab 10mg) is classified here; higher doses (50 mg) and injectable forms are in L2B2 when used as cytostatics. Includes products containing tibolone.</p> <p>Products containing mifepristone are classified here if indicated as abortifacients alone, or with other indications, or in G3A6 if indicated for emergency contraception.</p> <p>Products containing ulipristal are classified here if indicated for uterine fibroids, or in G3A6 if indicated for emergency contraception.</p>	<p>r2015</p>

<b>H2</b>	<b>SYSTEMIC CORTICOSTEROIDS</b>	
<b>H2A</b>	<b>SYSTEMIC CORTICOSTEROIDS, PLAIN</b>	
	Includes all systemic products containing one or more corticosteroid(s) and no other active ingredient, with or without lignocaine.	
H2A1	<b>Injectable corticosteroids, plain</b>	R1993
H2A2	<b>Oral corticosteroids, plain</b>	R1993
H2A3	<b>Other systemic corticosteroids, plain</b>	r2017
	Includes suppositories. Corticosteroids to treat inflammatory intestinal disorders are classified in A7E2.	
<b>H2B</b>	<b>SYSTEMIC CORTICOSTEROID COMBINATIONS</b>	r201 <del>97</del>
	Systemic products containing one or more corticosteroid(s) and one or more other active ingredient(s) (eg antihistamine). Also includes extracts containing natural corticosteroids, but excluding products classified in the following groups:	
	A7E2 – Intestinal anti-inflammatory agents	
	H4X – Liver extracts with small doses of corticosteroids (mainly in Italy).	
	G3X - Gland extracts (mammary, placenta, etc) and corticoid extracts mainly indicated for sexual disorders.	
	M1B - Corticosteroids with anti-inflammatory agents, analgesics, muscle relaxants, etc.	
	R1B – Systemic nasal preparations	
	R3D, R3F, R3L <del>32</del> - Anti-asthmatic inhalants acting topically on the bronchioles.	

<b>J4</b>	<b>ANTIMYCOBACTERIALS</b>	R1993
<b>J4A</b>	<b>ANTITUBERCULAR PRODUCTS</b>	r2009
	<p>Includes all specific tubercular preparations as well as streptomycin and dihydrostreptomycin. Other antibacterials such as viomycin and cycloserine which are indicated specifically for tuberculosis are included as well as rifampicin and rifamycin where they are used mostly as tuberculostatics. Where rifampicin and rifamycin are indicated for several conditions, then they are classified in J1M.</p> <p>The definition of ‘single ingredient’ means that only one specific antitubercular drug is present in the product. For example, if a product contains an antitubercular substance and also pyridoxine, this is a single ingredient product and will be classified in J4A1.</p> <p>Kits include various different tablets or forms with different ingredients. Fixed dose products contain the ingredients in one dosage form.</p>	
J4A1	<b>Antituberculars, single ingredient</b>	I2000
J4A2	<b>Antituberculars, kits, four or more ingredients</b>	I2000
J4A3	<b>Antituberculars, kits, three ingredients</b>	I2000
J4A4	<b>Antituberculars, kits, two ingredients</b>	I2000
J4A5	<b>Antituberculars, fixed dose, four or more ingredients</b>	I2000
J4A6	<b>Antituberculars, fixed dose, three ingredients</b>	I2000
J4A7	<b>Antituberculars, fixed dose, two ingredients</b>	I2000
J4A9	<b>Antituberculars, others</b>	I2000
<b>J4B</b>	<b>DRUGS FOR THE TREATMENT OF LEPROSY</b>	r20198
	<p>Includes preparations used for the treatment of leprosy (eg aldesulphone, clofazimine, dapsone). Products containing thalidomide for cancer are classified in L1X29 and for erythema nodosum leprosum (ENL) in L4X. Products for both cancer and ENL are classified in L1X29.</p>	

<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	R1994
<b>L1</b>	<b>ANTINEOPLASTICS</b>  Includes all preparations mainly indicated for the treatment of cancers and all packs specifically produced for use in anticancer therapy <b>eg special anticancer packs of antibiotics.</b>	R2003
<b>L1A</b>	<b>ALKYLATING AGENTS</b>  Includes nitrogen mustard analogues (eg chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine, trofosfamide), ethylene imines (eg altretamine (hexamethylmelamine), carboquone, thiotepa, triaziquone), nitrosoureas (eg bendamustine, carmustine, fotemustine, lomustine, semustine, streptozocin), alkyl sulfonates (eg busulfan, mannosulfan, mitolactol, treosulfan), triazenes and analogues. Dacarbazine is classified in this group.	R2003
<b>L1B</b>	<b>ANTIMETABOLITES</b>  Includes folic acid analogues (eg methotrexate), pyrimidine analogues (eg capecitabine, capecitabine, carmofur, cytarabine, fluorouracil, tegafur) and purine analogues (eg fludarabine, mercaptopurine, tioguanine).  Methotrexate can also be classified in M1C for rheumatic conditions or in D for dermatological conditions.  Products containing topical fluorouracil for actinic keratosis are classified here.	r2016
<b>L1C</b>	<b>PLANT-BASED ANTINEOPLASTICS</b>  Includes products that contain plant-derived alkaloids, terpenes, lignans etc, or their derivatives/analogues.  Combination products containing substances from two fourth level classes of L1C are classified in the higher level class, eg a combination of a camptothecin with a podophyllotoxin is classified in L1C3.	R2016
<b>L1C1</b>	<b>Vinca alkaloid antineoplastics</b>  Includes products containing alkaloids (or their derivatives/analogues) that are derived from <i>Cantharanthus roseus</i> (Madagascan periwinkle), eg vinblastine, vincristine, vindesine, vinflunine, vinorelbine, etc.	I2016
<b>L1C2</b>	<b>Taxane antineoplastics</b>  Includes products containing diterpenes (or their derivatives/analogues) that are derived from species of <i>Taxus</i> (yew), eg cabazitaxel, docetaxel, paclitaxel, etc.	I2016

L1C3	<p><b>Camptothecin antineoplastics</b></p> <p>Includes products containing alkaloids (or their derivatives/analogues) derived from <i>Camptotheca acuminata</i> (happy tree), eg hydroxycamptothecin, irinotecan, topotecan, etc.</p>	I2016
L1C4	<p><b>Podophyllotoxin antineoplastics</b></p> <p>Includes products containing lignans (or their derivatives/analogues) derived from <i>Podophyllum</i> (May apple) species, eg etoposide, mitopodozide, teniposide, etc.</p>	I2106
L1C9	<p><b>Plant-based antineoplastics, other</b></p> <p>Includes antineoplastic products containing other plant chemicals (or their derivatives/analogues), eg colchicine derivatives such as demecolcine.</p> <p>Products for cancer containing omacetaxine mepisuccinate are classified here. Products for cancer containing <i>Brucea javanica</i> are classified here.</p> <p>Antineoplastic products that contain dried plant material or unrefined plant extracts are classified in L1X9.</p> <p>Antineoplastic products that are derived from natural sources other than plants, eg from bacteria or fungi, are classified elsewhere.</p>	I2016
L1D	<p><b>ANTINEOPLASTIC ANTIBIOTICS</b></p> <p>Includes eg aclarubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mithramycin, mitoxantrone, plicamycin, zorubicin.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified here.</p> <p>Products containing gemtuzumab ozogamicin and inotuzumab ozogamicin are classified in L1G9.</p>	r20198
L1F	<p><b>PLATINUM ANTINEOPLASTICS</b></p> <p>Includes products containing eg carboplatin, cisplatin, oxaliplatin.</p>	I2014

<b>L1G</b>	<p><b>MONOCLONAL ANTIBODY ANTINEOPLASTICS</b></p> <p><del>Includes products containing monoclonal antibodies for neoplasms eg alemtuzumab, bevacizumab, cetuximab, edrecolomab, ibritumomab, rituximab, trastuzumab, etc.</del></p> <p><del>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</del></p> <p><del>Brentuximab vedotin, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, tocitumomab iodine 131 and trastuzumab emtansine are classified here.</del></p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.</p>	<u>R#20198</u>
<u>L1G1</u>	<p><b><u>Monoclonal antibody antineoplastics, CD20</u></b></p> <p><u>Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc.</u></p>	<u>I2019</u>
<u>L1G2</u>	<p><b><u>Monoclonal antibody antineoplastics, VEGF/VEGFR</u></b></p> <p><u>Includes products containing bevacizumab, ramucirumab, etc.</u></p>	<u>I2019</u>
<u>L1G3</u>	<p><b><u>Monoclonal antibody antineoplastics, HER-2</u></b></p> <p><u>Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab emtansine, etc.</u></p>	<u>I2019</u>
<u>L1G4</u>	<p><b><u>Monoclonal antibody antineoplastics, EGFR</u></b></p> <p><u>Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.</u></p>	<u>I2019</u>
<u>L1G5</u>	<p><b><u>Monoclonal antibody antineoplastics, PD-1/PD-L1</u></b></p> <p><u>Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc.</u></p>	<u>I2019</u>
<u>L1G9</u>	<p><b><u>Monoclonal antibody antineoplastics, other</u></b></p> <p><u>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc.</u></p> <p><u>Includes antibody drug conjugates (ADCs) if not classified with the target class</u></p>	<u>I2019</u>

(brentuximab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin).  
Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).

Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, siltuximab, tositumomab, tositumomab iodine-131, etc.

Products containing alemtuzumab and indicated for cancer only are classified here.  
Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.

**L1H**

**PROTEIN KINASE INHIBITOR ANTINEOPLASTICS**

R#201  
98

~~Includes protein kinase inhibitors for neoplasms, eg axitinib, crizotinib, dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, ribociclib, ruxolitinib, sorafenib, sunitinib, temsirolimus, vandetanib, vemurafenib, etc.~~

~~Products containing both ribociclib and letrozole are classified here.~~

Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.

L1H1

**Protein kinase inhibitor antineoplastics, BCR-ABL**

I2019

Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.

L1H2

**Protein kinase inhibitor antineoplastics, EGFR**

I2019

Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.

L1H3

**Protein kinase inhibitor antineoplastics, ALK**

I2019

Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.

L1H4

**Protein kinase inhibitor antineoplastics, BRAF/MEK**

I2019

Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc.

L1H5

**Protein kinase inhibitor antineoplastics, CDK 4/6**

I2019

	<u>Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.</u>	
<u>L1H9</u>	<b><u>Protein kinase inhibitor antineoplastics, other</u></b>	<u>I2019</u>
	<u>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2, JAK 1-2, BTK, Pi3K, etc.</u>	
	<u>Includes acalabrutinib, apatinib, axitinib, cabozantinib, everolimus, ibrutinib, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.</u>	
<b>L1J</b>	<b>PROTEASOME INHIBITOR ANTINEOPLASTICS</b>	I2018
	Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.	
<b>L1X</b>	<b>ALL OTHER ANTINEOPLASTICS</b>	R2018
L1X1	<b>Alternative preparations for cancer therapy</b>	r2018
	Includes products derived from Viscum (mistletoe).	
<u>L1X2</u>	<b><u>Lidomide antineoplastics</u></b>	<u>I2019</u>
	<u>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</u>	
	<u>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</u>	
L1X3	<b>HDAC inhibitor antineoplastics</b>	I2018
	Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.	
<u>L1X4</u>	<b><u>PARP inhibitor antineoplastics</u></b>	<u>I2019</u>
	<u>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</u>	
<u>L1X5</u>	<b><u>CAR T-cell therapy antineoplastics</u></b>	<u>I2019</u>
	<u>Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.</u>	

L1X8	<p><b>Photosensitisers for cancer therapy</b></p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, <u>methoxsalen</u>, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p><u>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</u></p> <p>Products containing vertoporfin for macular degeneration are classified in S1P.</p>	r2019 8
L1X9	<p><b>All other antineoplastics</b></p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p><u>Includes products containing hedgehog pathway inhibitors, eg glasdegib, sonidegib, vismodegib, etc. Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified here. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are in L4X. CAR T cell therapies are classified here, for example axicabtagene ciloleucel, tisagenlecleucel T.</u></p>	r2019 8

<b>L2</b>	<b>CYTOSTATIC HORMONE THERAPY</b>	I1994
	Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens.	
<b>L2A</b>	<b>CYTOSTATIC HORMONES</b>	I1994
L2A1	<b>Cytostatic oestrogens</b>	I1994
L2A2	<b>Cytostatic progestogens</b>	I1994
L2A3	<b>Cytostatic gonadotrophin-releasing hormone analogues</b>	R1995
	Buserelin, deslorelin, goserelin, nafarelin, leuprorelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C.	
L2A9	<b>Other cytostatic hormones</b>	I1994
	Includes substances such as drostanolone, testolactone.	
<b>L2B</b>	<b>CYTOSTATIC HORMONE ANTAGONISTS</b>	I1994
L2B1	<b>Cytostatic anti-oestrogens</b>	R1997
	Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene.	
L2B2	<b>Cytostatic anti-androgens</b>	I1994
	Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here.	
L2B3	<b>Cytostatic aromatase inhibitors</b>	r201 <del>98</del>
	Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole.	
	Products containing both ribociclib and letrozole are classified in L1H <del>5</del> .	
L2B9	<b>Other cytostatic hormone antagonists</b>	R2003
	Includes fulvestrant.	

<b>L4</b>	<b>IMMUNOSUPPRESSANTS</b>	R2010
<b>L4A</b>	Out of use; can be reused from 2013.	D2010
<b>L4B</b>	<b>ANTI-TNF PRODUCTS</b>  Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis.  Products containing apremilast <u>for psoriatic conditions only</u> are classified in <del>L4X.D5B</del> .	r201 <u>98</u>
<b>L4C</b>	<b>INTERLEUKIN INHIBITORS</b>  Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept.  Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes).  Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. Products containing tocilizumab and indicated for both arthritic conditions and also giant cell arteritis are classified in M1C. Products containing secukinumab or ustekinumab and indicated for <u>skin conditions such as psoriasis</u> and also other <u>non-skin</u> conditions, eg <u>rheumatoid</u> arthritis, are classified here. <u>Psoriatic arthritis is defined as a skin condition.</u>  Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A.  <u>Products containing mepolizumab for asthma only or for asthma and EGPA (eosinophilic granulomatosis with polyangiitis) are classified in R3M.</u>  <u>Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here.</u>	r201 <u>98</u>

<p><b>L4X</b></p>	<p><b>OTHER IMMUNOSUPPRESSANTS</b></p> <p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p>Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p>Products containing apremilast <u>for psoriatic skin conditions only, are classified in D5B, are classified here. Psoriatic arthritis is defined as a skin condition.</u></p> <p>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1X<del>29</del>. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1X<del>29</del>. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p>Corticosteroids are not classified here.</p>	<p>r201<del>98</del></p>
-------------------	---	--------------------------

<b>M1C</b>	<p><b>SPECIFIC ANTI-RHEUMATIC AGENTS</b></p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p>Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p>Products containing anti-TNF substances are classified in L4B.</p> <p>Products containing tofacitinib, and indicated for rheumatoid arthritis, are classified here.</p> <p>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg anakinra. Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p><del>Products containing apremilast are classified in L4X.</del></p> <p><u>Psoriatic arthritis is defined as a skin condition.</u></p>	r201 <del>9</del> 8
------------	---	---------------------

<b>M5</b>	<b>OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</b>	
<b>M5A</b>	Out of use; can be reused from 1996.	D1993
<b>M5B</b>	<b>BONE CALCIUM REGULATORS</b>	R2002
	Calcitonin products are classified in H4A. Products containing calcium only are classified in A12A and fluoride products are classified in A12C2.	
<b>M5B1</b>	Out of use; can be reused from 2010.	D2007
<b>M5B2</b>	Out of use; can be reused from 2010.	D2007
<b>M5B3</b>	<b>Bisphosphonates for osteoporosis and related disorders</b>	I2007
	Includes products indicated and used mainly for osteoporosis and Paget's disease, eg those containing alendronic acid, etidronic acid, ibandronic acid, risedronic acid, zoledronic acid, when indicated for these conditions. Combinations of bisphosphonates with calcium, calcitriol or colecalciferol are also classified here.	
<b>M5B4</b>	<b>Bisphosphonates for tumour-related calcium disorders</b>	I2007
	Includes products indicated and used mainly for tumour-related calcium disorders (eg hypercalcaemia of malignancy) eg those containing clodronic acid, etidronic acid, ibandronic acid, pamidronic acid, zoledronic acid when indicated for these conditions.	
<b>M5B9</b>	<b>Other bone calcium regulators</b>	I2002
	Includes other specific products which are used for osteoporosis (eg ipriflavone).	
<b>M5X</b>	<b>ALL OTHER MUSCULOSKELETAL PRODUCTS</b>	<del>R201</del> 906
	Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.	
	Includes hydroquinine indicated for restless leg syndrome.	
	Includes herbal products used for musculoskeletal pain.	

Products containing burosumab for X-linked hypophosphataemia are classified here.

<b>N7</b>	<b>OTHER CNS DRUGS</b>	R1996
<b>N7A</b>	<p><b>MULTIPLE SCLEROSIS PRODUCTS</b></p> <p>Products containing alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, laquinimod, teriflunomide, etc, and indicated for multiple sclerosis only, are classified here.</p> <p>Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified here.</p> <p>Products containing alemtuzumab and indicated for cancer only, are classified in L1G9.</p> <p>Products containing daclizumab and indicated for multiple sclerosis and also other conditions are classified here. Products containing daclizumab for use in kidney transplantation only are classified in L4C.</p> <p>Products containing beta interferons and indicated for multiple sclerosis only are classified here. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified in L3B2.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified in L1D.</p> <p>Products containing fampridine for improvement in walking in multiple sclerosis are classified in N7X.</p> <p>Products containing other substances, eg corticosteroids, immunosuppressants such as azathioprine, that have multiple uses, are classified elsewhere.</p>	R2019 7
<b>N7B</b>	<p><b>ANTISMOKING PRODUCTS</b></p> <p>Includes products used to stop smoking.</p>	
<b>N7C</b>	<p><b>ANTIVERTIGO PRODUCTS</b></p> <p>Includes betahistine, cinnarizine and flunarizine when indicated for vertigo and Meniere's disease.</p>	I1996
<b>N7D</b>	<b>ANTI-ALZHEIMER PRODUCTS</b>	I1998
<b>N7D1</b>	<b>Anti-Alzheimer products, cholinesterase inhibitors</b>	R2003
	Includes eg donepezil, galantamine, rivastigmine and tacrine.	
<b>N7D9</b>	<b>All other anti-Alzheimer products</b>	I1998

	Includes all other products specifically used for Alzheimer's disease.	
<b>N7E</b>	<b>DRUGS USED IN ALCOHOL DEPENDENCE</b>  Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here.	R2002
<b>N7F</b>	<b>DRUGS USED IN OPIOID DEPENDENCE</b>  Includes naltrexone, except when used in alcohol dependence (use N7E).	R2002
<b>N7X</b>	<b>ALL OTHER CNS DRUGS</b>  Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in the class. Products containing gabapentin or pregabalin are classified in N3A if indicated for both neuropathic pain and epilepsy.  Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here.  Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here.  Products indicated for amyotrophic lateral sclerosis (ALS) are classified here.	r2018

<b>R3C</b>	<b>NON-STEROIDAL RESPIRATORY ANTI-INFLAMMATORIES</b>	r2016
	This group contains respiratory antihistamines and non-steroidal respiratory anti-inflammatory products. It includes azelastine, cromoglycic acid, ketotifen, levocabastine, and tranilast. In Japan only, terfenadine is included in this group. In other countries it is classified in R6A. Excluded are combinations of these compounds with B2-agonists (R3E).	
R3C1	<b>Non-steroidal respiratory anti-inflammatories, inhalant</b>	
R3C2	<b>Non-steroidal respiratory anti-inflammatories, systemic</b>	
<b>R3D</b>	<b>CORTICOIDS</b>	r201 <del>9</del> 6
	Excluded are combinations of corticoids with B2-agonists (R3F) and LAMA/LABA combinations (R3L <del>3</del> 2).	
R3D1	<b>Corticoids, inhalant</b>	R2007
	Includes plain inhalant corticosteroids only. Also includes products indicated for both rhinitis and asthma.	
R3D2	<b>Corticoids, systemic</b>	r201 <del>9</del> 6
	This subgroup includes combinations only, with the exception of those classified in R3F and R3L <del>3</del> 2.	
	Plain systemic corticosteroids are classified in H2A.	
<b>R3E</b>	<b>B2-AGONIST AND R3C COMBINATIONS</b>	r2016
R3E1	<b>B2-agonist and R3C combinations, inhalant</b>	r2016
R3E2	<b>B2-agonist and R3C combinations, systemic</b>	r2016
<b>R3F</b>	<b>B2-AGONIST AND CORTICOID COMBINATIONS</b>	r201 <del>9</del> 6
	Combinations of LAMA/LABAs with corticosteroids are classified in R3L <del>3</del> 2.	
R3F1	<b>B2-agonist and corticoid combinations, inhalant</b>	r2016
R3F2	<b>B2-agonist and corticoid combinations, systemic</b>	r2016
<b>R3G</b>	Out of use	D2016
R3G1	Out of use	D2002

R3G2	Out of use	D2016
------	------------	-------

R3G3	Out of use	D2016
R3G4	Out of use	D2016
<b>R3H</b>	<b>PDE4 INHIBITORS FOR ASTHMA/COPD</b>	I2005
	Includes cilomilast, roflumilast.	
R3H1	<b>PDE4 inhibitors for asthma/COPD, inhalant</b>	I2005
R3H2	<b>PDE4 inhibitors for asthma/COPD, systemic</b>	I2005
<b>R3I</b>	<b>DEVICES FOR ASTHMATIC CONDITIONS</b>	R2001
	This excludes nebulising machines/nebulators which are classified in V7A.	
<b>R3J</b>	<b>ANTILEUKOTRIENE ANTI-ASTHMATICS</b>	R2004
	Includes montelukast, pranlukast, zafirlukast, and 5-lipoxygenase inhibitors such as zileuton when indicated for asthma.	
R3J1	<b>Antileukotriene anti-asthmatics, inhalant</b>	R1998
R3J2	<b>Antileukotriene anti-asthmatics, systemic</b>	R1998
<b>R3K</b>	<b>ANTICHOLINERGICS, PLAIN</b>	I2016
R3K1	<b>Short-acting anticholinergics, plain, inhalant</b>	I2016
	Includes products containing eg, ipratropium bromide, oxitropium bromide, etc	
R3K2	<b>Long-acting anticholinergics, plain, inhalant</b>	I2016
	Includes products containing eg acclidinium bromide, flutropium bromide, glycopyrronium bromide, tiotropium bromide, umeclidinium bromide, etc.	
R3K3	<b>Anticholinergics, plain, systemic</b>	I2016
	Includes products containing anticholinergics (short- or long-acting) for systemic use.	

<b>R3L</b>	<b>ANTICHOLINERGICS IN COMBINATION WITH B2-AGONISTS</b>	I2016
R3L1	<b>Short-acting anticholinergic combinations with short-acting B2-agonists, inhalant</b>  Includes products containing eg ipratropium bromide with fenoterol, ipratropium bromide with salbutamol, etc	I2016
R3L2	<b>Long-acting anticholinergic combinations with long-acting B2-agonists, inhalant</b>  Includes products containing eg aclidinium bromide with formoterol, glycopyrronium bromide with indacaterol, tiotropium bromide with formoterol, tiotropium bromide with olodaterol, umeclidinium bromide with vilanterol, etc. These are known as LAMA/LABA combinations.  <del>LAMA/LABA combinations also containing a corticosteroid are classified here.</del>	<del>I2016</del>
<u>R3L3</u>	<u><b>Long-acting anticholinergic combinations with both long-acting B2-agonists and with corticosteroids, inhalant</b></u>  <u>Includes products containing a triple combination of a long-acting anticholinergic, a long-acting B2-agonist and a corticosteroid. Includes glycopyrronium bromide plus formoterol plus beclomethasone or budesonide, tiotropium bromide plus formoterol plus ciclesonide, umeclidinium bromide plus vilanterol plus fluticasone, etc.</u>	<u>I2019</u>
R3L8	<b>Anticholinergic combinations with B2-agonists, systemic</b>  Includes products containing anticholinergics (short- or long-acting) in combination with B2-agonists (short- or long-acting) for systemic use.	I2016
R3L9	<b>Anticholinergic combinations with B2-agonists, inhalant, other</b>  Includes products containing anticholinergics in combination with B2-agonists that cannot be classified in the other R3L classes.	I2016
<b>R3M</b>	<b>INTERLEUKIN INHIBITOR ANTI-ASTHMATICS</b>  Includes products containing interleukin inhibitors for asthma, eg benralizumab, mepolizumab, reslizumab, etc.  <u>Products containing mepolizumab for asthma only and for asthma and EGPA (eosinophilic granulomatosis with polyangiitis) are classified here.</u>	<del>I2016</del>
<b>R3X</b>	<b>ALL OTHER ANTI-ASTHMA AND COPD PRODUCTS</b>	R2000
R3X1	<b>All other anti-asthma and COPD products, inhalant</b>	R2003

R3X2	<p>This subgroup includes anti-asthmatic cigarettes.</p> <p><b>All other anti-asthma and COPD products, systemic</b></p> <p>Includes products containing alpha-1-proteinase inhibitor (alpha-1-antitrypsin).</p>	r2018
------	--	-------

V3X

**ALL OTHER THERAPEUTIC PRODUCTS**

rR201  
907

Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.

4<sup>th</sup> level used only in Germany and Hungary.